Sex: M
Vaccine: COVID19
Symptoms: Therapeutic product effect decreased
Clinical narrative: Drug effect decreased; This spontaneous case was reported by a consumer and describes the occurrence of THERAPEUTIC PRODUCT EFFECT DECREASED (Drug effect decreased) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Ulcerative colitis and Panuveitis.    No Medical History information was reported.   In April 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In May 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced THERAPEUTIC PRODUCT EFFECT DECREASED (Drug effect decreased). At the time of the report, THERAPEUTIC PRODUCT EFFECT DECREASED (Drug effect decreased) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  No concomitant medications were reported. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. The patient experienced Humira not working well as well as it did. No treatment medications were reported.  Company comment  This is a spontaneous case reported by a consumer, concerning a male patient of unknown age, with no medical history reported, who experienced the unexpected, non serious event of THERAPEUTIC PRODUCT EFFECT DECREASED (Drug effect decreased) unknown days after receiving the second dose of mRNA-1273 Vaccine in the covid 19 vaccination series. The primary 2 doses of m RNA1273 vaccine was given at an interval of about 01 month. The patient was started on ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose for ulcerative colitis, which remains as a confounder.  Details of risk factors, co morbidities, clinical course, concomitant medications and treatment details were not reported. The outcome of the event was unknown. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case reported by a consumer, concerning a male patient of unknown age, with no medical history reported, who experienced the unexpected, non serious event of THERAPEUTIC PRODUCT EFFECT DECREASED (Drug effect decreased) unknown days after receiving the second dose of mRNA-1273 Vaccine in the covid 19 vaccination series. The primary 2 doses of m RNA1273 vaccine was given at an interval of about 01 month. The patient was started on ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose for ulcerative colitis, which remains as a confounder.  Details of risk factors, co morbidities, clinical course, concomitant medications and treatment details were not reported. The outcome of the event was unknown. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.